[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

652.O1.6 Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Multiple Myeloma - Novel Strategies for the Treatment of Multiple Myeloma

Program: Oral and Poster Abstracts
Type: Oral
Sunday, December 5, 2010: 4:30 PM-6:00 PM
314 (Orange County Convention Center)
Moderators:
Ross D Brown, DPhil, Royal Prince Alfred Hospital and Suzanne Lentzsch, MD, PhD, University of Pittsburgh Cancer Institute
4:30 PM
Dual Targeting of -TORC1 and -TORC2 as a New Strategy In the Treatment of Multiple Myeloma

Patricia Maiso, PhD1, AbdelKareem Azab, PhD1*, Yang Liu, PhD2*, Yong Zhang, PhD2*, Feda Azab2*, Antonio Sacco2*, Hai T Ngo2*, Yi Liu, PhD3*, Brittany Morgan2*, Christian Rommel, PhD3*, Kenneth C. Anderson, MD2, Aldo M. Roccaro, MD, PhD2 and Irene M. Ghobrial, MD2

1Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
3Intellikine, La Jolla, CA

4:45 PM
Biology and Therapeutic Targeting of Sp1 Transactivation In Myeloma

Mariateresa Fulciniti, PhD1*, Samir B. Amin, MBBS1*, Puru Nanjappa1*, Scott J. Rodig, MD, PhD2, Teru Hideshima3, Jagannath Pal, PhD4*, Varuna Mohan1*, Keeyun Lee1*, Masood Shammas, Ph.D4*, Stephane Minvielle5*, Rao Prabhala1*, Hervé Avet-Loiseau, MD, PhD6, Li Cheng1*, Kenneth C. Anderson, MD3 and Nikhil C. Munshi, MD7

1Dana Farber Cancer Institute, Boston, MA
2Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
3Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Dana-Farber Cancer Institute; VA Boston Healthcare System, Boston, MA
5U, Nantes, France
6University Hospital of Nantes, Nantes, France
7Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

5:00 PM
C/EBPb Is a Critical Mediator of Resistance to IMiD® Immunomodulatory Compounds and Affected by IMiD Compounds Via Control of Protein Translation

Shirong Li, PhD1*, Rekha Pal, PhD2*, Sara Monaghan, MD3*, Peter H Schafer4*, Hongjiao Ouyang, DDS, PhD5*, Markus Y. Mapara, MD, PhD1 and Suzanne Lentzsch, MD, PhD2

1Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA
2Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA
3Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA
4Translational Development, Celgene Corporation, Summit, NJ
5Center for Bone Biology, VA Pittsburgh Healthcare System, Pittsburgh, PA

5:15 PM
TP53 Positively Regulates Cell Death through TRAILR2 (DR5) but Negatively through TRAILR1 (DR4) In Myeloma Cells

Sylvanie Surget, PhD, in, training1*, Patricia Gomez-Bougie1*, David Chiron, PhD, in, training1*, Robin Humphreys, PhD2*, Philippe Moreau3*, Steven Le Gouill3*, Jean-Luc Harousseau4, Regis Bataille, MD, PhD5*, Martine Amiot1* and Catherine Pellat-Deceunynck, PhD6

1Nantes Angers Cancer Center, Inserm UMR_S892, Nantes, France
2Human Genome Sciences, Rockville, MD
3Hematology Department, CHU de Nantes, Nantes, France
4Haematology, Centre anticancereux Rene Gauducheau, Saint Herblain, France
5Cancer Center, Angers, France
6CRCNA, INSERM UMR_S892, Nantes, France

5:30 PM
Germinal Center Specific Activation of K-Ras, Common In Multiple Myeloma, Is Selected Against and Is Not Sufficient to Initiate Plasma Cell Transformation In Mice

Chelsea D. Mullins, BSci1*, Michael Tomasson, MD2, Lan Lu, MSci3*, Mack Y. Su4*, Vishwanathan Hutchagowder, PhD4*, Ravi Vij, MBBS, MD5, Shashikant Kulkarni, PhD6* and Liang Chu, PhD4*

1Div. of Oncology, Sect. of BMT, Washington University School of Medicine, St. Louis, MO
2Div. of Oncology, Sect. of BMT, Washington University, Saint Louis, MO
3Internal Medicine, Washington University School of Medicine, Saint Louis, MO
4Div. of Oncology, Sect. of BMT", Washington University School of Medicine, Saint Louis, MO
5Division of Oncology, Washington University School of Medicine, Saint Louis, MO
6Dept. of Medicine, Washington Univ. School of Med., Saint Louis, MO

5:45 PM
Studies of BP-1-102, a Novel Direct Small-Molecule Inhibitor of Stat3 Demonstrates Substantial Anti-Myeloma Pre-Clinical Activity

Victor H Jimenez-Zepeda, MD, PD1, Zhi Hua Li2*, Brent DG Page3*, Seda Zeng2*, Ellen Wei2*, Chungyee Leung-Hagesteijn2*, James Turkson4*, Patrick T. Gunning5* and Suzanne Trudel, MD, MSC, FRCPC6

1DMOH, Princess Margaret Hospital, Toronto, Ontario, ON, Canada
2Dmoh, Princess Margaret Hospital, Toronto, Ontario, ON, Canada
3Department of Chemistry,, University of Toronto at Mississauga, Mississauga, ON, Mississauga, ON, Canada
4Department of Molecular Biology and Microbiology, Burnett College of Biomedical Sciences,, University of Central Florida, Orland, Orlando, FL
5Department of Chemistry,, University of Toronto at Mississauga, Mississauga, ON, Toronto, Ontario, ON, Canada
6McLaughlin Centre for Molecular Medicine, Princess Margaret Hospital, Toronto, ON, Canada

*signifies non-member of ASH